Kidney cancer drug combo trial halted early – what we know
NCT ID NCT06114940
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 26 times
Summary
This study tested a combination of two drugs (toripalimab and lenvatinib) given before and after kidney cancer surgery in 17 people with different stages of kidney cancer. The goal was to see if the treatment could shrink or eliminate the tumor before surgery and help control the disease afterward. The trial was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA (RCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China
Nanjing, Jiangsu, 210000, China
Conditions
Explore the condition pages connected to this study.